Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Butterfly Network (BFLY) and Disc Medicine (IRON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), Butterfly Network (BFLY – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AbbVie (ABBV)
In a report released today, Matt Phipps from William Blair maintained a Buy rating on AbbVie. The company’s shares closed last Monday at $232.66.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $253.06, implying an 8.3% upside from current levels. In a report issued on February 19, Barclays also initiated coverage with a Buy rating on the stock with a $275.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Butterfly Network (BFLY)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Butterfly Network today. The company’s shares closed last Monday at $3.70.
According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Butterfly Network with a $5.75 average price target, which is a 57.5% upside from current levels. In a report issued on February 27, TipRanks – Google also upgraded the stock to Buy with a $5.50 price target.
Disc Medicine (IRON)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Disc Medicine on February 27 and set a price target of $125.00. The company’s shares closed last Monday at $65.56, close to its 52-week high of $68.73.
According to TipRanks.com, Kluska is a 5-star analyst with an average return of
Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $104.55, which is a 61.2% upside from current levels. In a report issued on February 13, LifeSci Capital also maintained a Buy rating on the stock with a $100.00 price target.
